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1. Introduction
Liver-directed therapies such as selective internal radi-
ation therapy (SIRT, also known as radioembolisation)
are investigational treatments that have the potential
to improve local control and survival in metastastic
colorectal cancer (mCRC) conﬁned to the liver.
Combining systemic chemotherapy with locoregional
treatment has succeeded in signiﬁcantly increasing the
tumoral response (as measured by RECIST) and the
number of patients eligible for liver resection compared
with chemotherapy alone. However, these outcomes,
while impressive, need validation in phase III clinical
trials designed to assess the clinical beneﬁt for patients
with mCRC. Against a backdrop of escalating costs
associated with multiple chemotherapies combined with
biologicals, there is much controversy regarding the
sequencing and combination of drugs for optimal effect
without compromising safety. The role of combining
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systemic treatments with liver-directed SIRT still needs
to be deﬁned.
2. FOXFIRE and SIRFLOX
There are two on-going multicentre randomised clinical
trials: FOXFIRE (5-Fluorouracil, OXaliplatin and Folinic
acid +/− Interventional Radio-Embolisation) 1,2 and SIR-
FLOX (SIR-Spheres + FOLFOX versus FOLFOX alone) 3
which aim to provide the evidence for the safety and
efﬁcacy of SIRT combined with chemotherapy in the ﬁrst-
line setting in patients with unresectable liver only or
liver-predominant metastatic colorectal cancer.
Both studies have a similar design to allow for
the combined analysis of overall survival (the primary
endpoint) in more than 940 patients. In addition,
progression-free survival, liver-speciﬁc progression-free
survival, response and liver resection rates, safety and
toxicity, healthcare costs/health-economic analyses as
well as quality of life (measured using EQ-5D and EORTC
QLQ-30 instruments) will be assessed as secondary
endpoints.
The patient population is limited to those considered
to have liver-only or liver-dominant metastatic disease as
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Table 1 – Patient population: inclusion criteria (FOXFIRE study)
• Histologically conﬁrmed colorectal cancer with liver-only or liver-dominant metastatic disease (for a deﬁnition of the
permitted extent of extrahepatic metastases see below)
• Not amenable to curative liver surgical resection at the time of study entry, which must be agreed at local
multi-disciplinary team (MDT) meeting with hepatic surgery and radiology representation.
• Patients are permitted to have a synchronous primary colorectal tumour, which should be potentially resectable
following protocol therapy
• WHO performance status of 0−1
• Eligible for systemic chemotherapy as ﬁrst-line treatment for metastatic colorectal cancer
• Adequate haematological, renal and hepatic function as follows:
Haematological: Neutrophils >1.5×109/L; Platelets >100×109/L
Renal: Creatinine <1.5×ULN
Hepatic: Bilirubin 30mmol/L; Albumin 30 g/L
• Patients are permitted to have limited extra-hepatic metastases, deﬁned as follows:
• metastases in the lung (5 metastases)* and should be, in the opinion of either the local MDT or following central
review, amenable to future deﬁnitive local therapy (surgery or ablation)
• And/or a single site of other extra-hepatic disease e.g. multiple lymph nodes in one lymph node region*
• PET or biopsy negative lesions
(Individual cases that fall outside these criteria should be discussed with the Trials Ofﬁce)
• Life expectancy of at least 3 months without any active treatment
• Prior chemotherapy for metastatic colorectal cancer is not allowed. Patients may have received both adjuvant
chemotherapy and/or radiotherapy following resection of the primary colorectal cancer, provided the last dose of
chemotherapy and/or radiotherapy was administered at least 6 months prior to entry into this study
• Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually
active using an acceptable method of contraception
• Male patients must be surgically sterile or if sexually active and having a pre-menopausal partner must be using an
acceptable method of contraception
• Aged 18 years or older
• Willing and able to provide written informed consent
*SIRFLOX study criteria: metastases in the lung (5 metastases of 1 cm each) and/or abdominal or perihepatic lymph
nodes (<2 cm in diameter)
deﬁned inTable 1 (i.e. borderline systemic disease), which
is not amenable to curative liver surgical resection at the
time of study entry. Patients in the UK FOXFIRE study
are permitted to have a synchronous primary colorectal
tumour, which should be potentially resectable following
protocol therapy. This practice is consistent with the UK
COIN trial which included 41% of patients with primary
tumour left in situ at the outset of ﬁrst-line systemic
therapy. 4
In both trials, patients are stratiﬁed by the presence or
absence of extra-hepatic metastases, degree of liver in-
volvement, institution, and planned use of bevacizumab
or cetuximab. Patients are randomised to treatment
with standard ﬁrst-line mFOLFOX or mFOLFOX plus SIRT
(Table 2). As there is limited experience integrating SIRT
and concurrent biologicals, adding bevacizumab and/or
cetuximab is recommended at least 4 cycles after SIRT.
To date, no safety concerns have been identiﬁed from the
provisional analysis of safety in more than 300 patients.
Early indications suggest that SIRT when used in the
ﬁrst-line setting may be tolerated even better than for
patients with chemorefractory disease whose liver has
been compromised by successive lines of chemotherapy.
In parallel, a number of translational substudies are
ongoing at various institutions to assess changes in
tumour and liver perfusion using dynamic contrast-
enhanced ultrasonography (DCE-US; Hammersmith Hos-
pital) or perfusion CT (Oxford Unviversity 5). Blood and
tissue samples from FOXFIRE and the New-EPOC clinical
trial 6 are being stored at Southampton for analysis
under the combined Trans-EPOC (funded by Cancer
Research UK).
Supported by positive guidance from UK NICE on re-
cruitment, 1 FOXFIRE has served to establish a number of
centres of excellence for SIRT in the UK. In every country
where such studies are now ongoing, new collaborations
have evolved (e.g. between chemotherapy only centres
and liver units), thereby improving the quality of care and
multi-disciplinary team interaction for patients overall,
beyond the clinical trials setting.
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Table 2 – Study design similarities and differences in the FOXFIRE and SIRFLOX protocols
SIRFLOX (Clinical trials identiﬁer: NCT00724503) FOXFIRE (Clinical trials identiﬁer: ISRCTN 83867919)
• SIR-Spheres microspheres implanted day 3−4 of Cycle 1 • SIR-Spheres microspheres implanted day 3−4 of Cycle 2 or 3
• Oxaliplatin administered at 60mg/m2 for Cycles 1−3 in the
SIR-Spheres microspheres + FOLFOX arm
• Oxaliplatin administered at 60mg/m2 for Cycles 1−3 in the
SIR-Spheres microspheres + OxMdG arm
• At the investigators’ discretion, bevacizumab may commence at
Cycle 4 in the test arm and at Cycle 1 (or per institutional
protocol) in the control arm
• At the investigators’ discretion, bevacizumab or cetuximab may
commence at Cycle 7 in the test arm and at Cycle 1 (or per
institutional protocol) in the control arm
• Treatment till disease progression • Treatment for 12 cycles
• CT scans every 8 weeks • CT scans: 3, 6, 8 months and then every 2 months
• Median overall survival in control arm >20 months • Median overall survival in control arm 16 months
• Participating centres: European Union, USA, Australia,
New Zealand
• Participating centres: UK
Medical and Sanoﬁ-Aventis as well as research grants
from Pﬁzer, bioTheranostics, MerckSerono KGA and
Sirtex Medical.
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